Pulse Explore Journal Club Debates Trending Researchers Journals

Join discussions, follow papers, and never miss your next session.

Download on theApp Store

Home Explore Journal Club Trending

⌘+K

Lack of Discernible Benefit of High-Dose Aspirin in the Treatment of Kawasaki Disease | Synapse

January 20, 2026Journal of the Pediatric Infectious Diseases Society0 citations

View Full Paper

Lack of Discernible Benefit of High-Dose Aspirin in the Treatment of Kawasaki Disease

LTLavina ThadaniNorthwestern University HKHuthaifah KhanNorthwestern University KKKwang-Youn KimNorthwestern University

Key Points

To evaluate the effectiveness of high-dose aspirin compared to low-dose aspirin in treating Kawasaki Disease.
Conducted a retrospective cohort study
Analyzed data from 460 children
Compared outcomes of low-dose vs. high-dose aspirin alongside IVIG treatment
No significant difference in coronary artery outcomes between low and high-dose aspirin
IVIG retreatment rates were similar in both groups
Supports the use of low-dose aspirin in acute-phase Kawasaki Disease

Abstract

Abstract In a retrospective single-center cohort study of 460 children with Kawasaki Disease, initial treatment with low-dose aspirin and IVIG resulted in similar coronary artery outcomes and IVIG retreatment rates compared to high-dose aspirin and IVIG. These findings support consideration of low-dose aspirin for the management of acute-phase Kawasaki Disease.

Ask AI

Helpful

Bookmark

Share

View Full Paper

Ask AI

Helpful

Bookmark

Share

View Full Paper

Cite This Study

Thadani et al. (Tue,) studied this question.

synapsesocial.com/papers/696f1ac19e64f732b51eef96 https://doi.org/https://doi.org/10.1093/jpids/piag002